The global pharmaceutical sector operates under a highly advanced and ever-evolving regulatory environment. With the emergence of new therapeutic modalities based on biologics, cell and gene therapies, and even artificial intelligence diagnostics, the role of national/regional regulators has transcended its Read More …
Tag: guideline
Risk Management is a “Living, Breathing” Obligation, FDA Official Warns
Baltimore – The main problem for medical device makers cited for regulatory issues is risk management. According to the keynote address presented by Keisha Thomas at the RAPS Quality Conference, where Ms. Thomas is currently Associate Director for Compliance and Read More …
The V-Model in Computer Systems Validation: Structural Mechanics, Differences, and Evolving into Computer Software Assurance
Computer Systems Validation (CSV) acts as the main regulatory control framework for guaranteeing that computerized systems utilized within GxP-regulated life science industries such as the pharmaceutical, biotech, and medical device industries function in a consistent, reliable manner that fully complies Read More …
A Comprehensive Analysis of ICH Q9(R1) and the Evolving Standards of Quality Risk Management
The formal adoption of the ICH Q9(R1) guideline in January 2023 represents a pivotal advancement in the global harmonization of pharmaceutical quality standards, addressing nearly two decades of implementation experience and evolving industrial complexities. Originally introduced in 2005, the ICH Read More …
The Strategic Transition to Quality 4.0: Integrating Digital Intelligence into Organizational Excellence
The global industrial landscape is presently navigating a foundational transformation, shifting from traditional quality management paradigms to a digitized, interconnected framework known as Quality 4.0. This evolution represents the alignment of quality management practices with the technological advancements of the Read More …
The Definitive Guide to CAPA Management: Remediating Ineffective Systems and Preventing Repeat Deviations
Executive Summary In the global pharmaceutical landscape of 2026, the Corrective and Preventive Action (CAPA) system is no longer viewed as a mere documentation exercise. It is the engine of continuous improvement. This guide explores why the WHO often cites Read More …
Modern Laboratory Data Integrity: LIMS, ALCOA+, and Preventing “Testing into Compliance”
The contemporary industrial landscape, particularly within the pharmaceutical and high-precision textile sectors, is currently undergoing a radical transformation driven by the convergence of stringent regulatory oversight and the urgent necessity for sustainable technological innovation. At the heart of this evolution Read More …
How to Source Pharmaceutical Raw Materials in Bangladesh: API Indenting Process & Supplier Qualification
This comprehensive guide details the structure, regulatory environment, and strategic operations of a pharmaceutical indenting firm in Bangladesh. Given the country’s status as a global generic drug hub, indenting is the “nervous system” that connects over 250 local manufacturers to Read More …
10 Must-Follow Change Control Rules in Pharmaceutical Manufacturing
1. No Change Without Formal Approval In pharmaceutical manufacturing, no change—whether related to process, material, equipment, or documentation—should be implemented without prior approval through a formal Change Control system. Regulatory authorities like Directorate General of Drug Administration and US Food Read More …
Avoid CAPA Failure: Critical Writing Considerations in Pharmaceutical Industry
CAPA (Corrective and Preventive Action) is not just a documentation exercise—it is a regulatory expectation under Pharmaceutical Quality System (PQS) as per World Health Organization, US Food and Drug Administration, and International Council for Harmonisation. 🧩 1. Define the Problem Read More …